Cardiac troponin I as predictor for cardiac and other mortality in the German randomized lung cancer screening trial (LUSI)
© 2024. The Author(s)..
Cardiac Troponin I (cTnI) could be used to identify individuals at elevated risk of cardiac death in lung cancer (LC) screening settings. In a population-based, randomized LC screening trial in Germany ("LUSI" study) serum cTnI was measured by high-sensitivity assay in blood samples collected at baseline, and categorized into unquantifiable/low (< 6 ng/L), intermediate (≥ 6-15 ng/L), and elevated (≥ 16 ng/L). Cox proportional-hazard models were used to estimate risk of all-cause and cardiac mortality with cTnI levels. After exclusion criteria, 3653 participants were included for our analyses, of which 82.4% had low, 12.8% intermediate and 4.8% elevated cTnI, respectively. Over a median follow up of 11.87 years a total of 439 deaths occurred, including 67 caused by cardiac events. Within the first 5 years after cTnI measurement, intermediate or elevated cTnI levels showed approximately 1.7 (HR = 1.69 [95% CI 0.57-5.02) and 4.7-fold (HR = 4.66 [1.73-12.50]) increases in risk of cardiac death relative to individuals with unquantifiable/low cTnI, independently of age, sex, smoking and other risk factors. Within this time interval, a risk model based on age, sex, BMI, smoking history and cTnI showed a combined area under the ROC curve (AUC) of 73.6 (58.1-87.3), as compared to 70.4 (53.3-83.5) for a model without cTnI. Over the time interval of > 5-10 years after blood donation, the relative risk associations with cTnI and were weaker. cTnI showed no association with mortality from any other (non-cardiac) cause. Our findings show that cTnI may be of use for identifying individuals at elevated risk specifically of short-term cardiac mortality in the context of LC screening.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Scientific reports - 14(2024), 1 vom: 26. März, Seite 7197 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cortés-Ibáñez, Francisco O [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers |
---|
Anmerkungen: |
Date Completed 28.03.2024 Date Revised 29.03.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41598-024-57889-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370214730 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370214730 | ||
003 | DE-627 | ||
005 | 20240330001500.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240328s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41598-024-57889-z |2 doi | |
028 | 5 | 2 | |a pubmed24n1355.xml |
035 | |a (DE-627)NLM370214730 | ||
035 | |a (NLM)38531926 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cortés-Ibáñez, Francisco O |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cardiac troponin I as predictor for cardiac and other mortality in the German randomized lung cancer screening trial (LUSI) |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.03.2024 | ||
500 | |a Date Revised 29.03.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a Cardiac Troponin I (cTnI) could be used to identify individuals at elevated risk of cardiac death in lung cancer (LC) screening settings. In a population-based, randomized LC screening trial in Germany ("LUSI" study) serum cTnI was measured by high-sensitivity assay in blood samples collected at baseline, and categorized into unquantifiable/low (< 6 ng/L), intermediate (≥ 6-15 ng/L), and elevated (≥ 16 ng/L). Cox proportional-hazard models were used to estimate risk of all-cause and cardiac mortality with cTnI levels. After exclusion criteria, 3653 participants were included for our analyses, of which 82.4% had low, 12.8% intermediate and 4.8% elevated cTnI, respectively. Over a median follow up of 11.87 years a total of 439 deaths occurred, including 67 caused by cardiac events. Within the first 5 years after cTnI measurement, intermediate or elevated cTnI levels showed approximately 1.7 (HR = 1.69 [95% CI 0.57-5.02) and 4.7-fold (HR = 4.66 [1.73-12.50]) increases in risk of cardiac death relative to individuals with unquantifiable/low cTnI, independently of age, sex, smoking and other risk factors. Within this time interval, a risk model based on age, sex, BMI, smoking history and cTnI showed a combined area under the ROC curve (AUC) of 73.6 (58.1-87.3), as compared to 70.4 (53.3-83.5) for a model without cTnI. Over the time interval of > 5-10 years after blood donation, the relative risk associations with cTnI and were weaker. cTnI showed no association with mortality from any other (non-cardiac) cause. Our findings show that cTnI may be of use for identifying individuals at elevated risk specifically of short-term cardiac mortality in the context of LC screening | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Biomarkers | |
650 | 4 | |a Lung cancer screening | |
650 | 4 | |a Mortality | |
650 | 4 | |a Myocardial infarction | |
650 | 4 | |a Risk assessment | |
650 | 4 | |a Troponin | |
650 | 7 | |a Troponin I |2 NLM | |
650 | 7 | |a Biomarkers |2 NLM | |
700 | 1 | |a Johnson, Theron |e verfasserin |4 aut | |
700 | 1 | |a Mascalchi, Mario |e verfasserin |4 aut | |
700 | 1 | |a Katzke, Verena |e verfasserin |4 aut | |
700 | 1 | |a Delorme, Stefan |e verfasserin |4 aut | |
700 | 1 | |a Kaaks, Rudolf |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 14(2024), 1 vom: 26. März, Seite 7197 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:26 |g month:03 |g pages:7197 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-024-57889-z |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2024 |e 1 |b 26 |c 03 |h 7197 |